FDA 483 - OneBlood, Inc. - June 06, 2025

OneBlood, Inc. in St Petersburg, FL, a blood bank, was cited for failing to submit biological product deviation reports within the required 45-day timeframe. An FDA review found 23 out of 282 reports were submitted late between December 2021 and June 2025. This issue is noted as a recurrent observation from a previous inspection.